854 related articles for article (PubMed ID: 19370562)
41. Safety/Tolerability and efficacy of rivastigmine in taiwanese patients with Alzheimer's disease: a prospective post-marketing surveillance study.
Chiu PY; Dai DE; Hsu HP; Lee C; Lin JJ; Kuo HC; Huang YC; Liu YC; Tsai CP
Clin Drug Investig; 2009; 29(11):729-38. PubMed ID: 19813776
[TBL] [Abstract][Full Text] [Related]
42. Rivastigmine transdermal patch: a review of its use in the management of dementia of the Alzheimer's type.
Dhillon S
Drugs; 2011 Jun; 71(9):1209-31. PubMed ID: 21711064
[TBL] [Abstract][Full Text] [Related]
43. Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia.
Parsons C; Lim WY; Loy C; McGuinness B; Passmore P; Ward SA; Hughes C
Cochrane Database Syst Rev; 2021 Feb; 2(2):CD009081. PubMed ID: 35608903
[TBL] [Abstract][Full Text] [Related]
44. Rivastigmine for dementia associated with Parkinson's disease.
Emre M; Aarsland D; Albanese A; Byrne EJ; Deuschl G; De Deyn PP; Durif F; Kulisevsky J; van Laar T; Lees A; Poewe W; Robillard A; Rosa MM; Wolters E; Quarg P; Tekin S; Lane R
N Engl J Med; 2004 Dec; 351(24):2509-18. PubMed ID: 15590953
[TBL] [Abstract][Full Text] [Related]
45. Cholinesterase inhibitors for dementia with Lewy bodies.
Wild R; Pettit T; Burns A
Cochrane Database Syst Rev; 2003; 2003(3):CD003672. PubMed ID: 12917981
[TBL] [Abstract][Full Text] [Related]
46. Memantine for dementia.
McShane R; Westby MJ; Roberts E; Minakaran N; Schneider L; Farrimond LE; Maayan N; Ware J; Debarros J
Cochrane Database Syst Rev; 2019 Mar; 3(3):CD003154. PubMed ID: 30891742
[TBL] [Abstract][Full Text] [Related]
47. Rivastigmine for vascular cognitive impairment.
Craig D; Birks J
Cochrane Database Syst Rev; 2005 Apr; (2):CD004744. PubMed ID: 15846730
[TBL] [Abstract][Full Text] [Related]
48. Rivastigmine transdermal patch 13.3 mg/24 h: a review of its use in the management of mild to moderate Alzheimer's dementia.
Frampton JE
Drugs Aging; 2014 Aug; 31(8):639-49. PubMed ID: 24989628
[TBL] [Abstract][Full Text] [Related]
49. Folic acid with or without vitamin B12 for cognition and dementia.
Malouf M; Grimley EJ; Areosa SA
Cochrane Database Syst Rev; 2003; (4):CD004514. PubMed ID: 14584018
[TBL] [Abstract][Full Text] [Related]
50. Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review.
Clegg A; Bryant J; Nicholson T; McIntyre L; De Broe S; Gerard K; Waugh N
Health Technol Assess; 2001; 5(1):1-137. PubMed ID: 11262420
[TBL] [Abstract][Full Text] [Related]
51. Dose effects associated with rivastigmine transdermal patch in patients with mild-to-moderate Alzheimer's disease.
Grossberg GT; Olin JT; Somogyi M; Meng X
Int J Clin Pract; 2011 Apr; 65(4):465-71. PubMed ID: 21309961
[TBL] [Abstract][Full Text] [Related]
52. Rivastigmine in Alzheimer's disease and Parkinson's disease dementia: an ADAS-cog factor analysis.
Weintraub D; Somogyi M; Meng X
Am J Alzheimers Dis Other Demen; 2011 Sep; 26(6):443-9. PubMed ID: 22009228
[TBL] [Abstract][Full Text] [Related]
53. Tacrine for Alzheimer's disease.
Qizilbash N; Birks J; López-Arrieta J; Lewington S; Szeto S
Cochrane Database Syst Rev; 2000; 1999(2):CD000202. PubMed ID: 10796507
[TBL] [Abstract][Full Text] [Related]
54. Memantine for dementia.
Areosa SA; Sherriff F
Cochrane Database Syst Rev; 2003; (1):CD003154. PubMed ID: 12535459
[TBL] [Abstract][Full Text] [Related]
55. Donepezil and rivastigmine in the treatment of Alzheimer's disease: a best-evidence synthesis of the published data on their efficacy and cost-effectiveness.
Wolfson C; Oremus M; Shukla V; Momoli F; Demers L; Perrault A; Moride Y
Clin Ther; 2002 Jun; 24(6):862-86; discussion 837. PubMed ID: 12117079
[TBL] [Abstract][Full Text] [Related]
56. Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials.
Kavirajan H; Schneider LS
Lancet Neurol; 2007 Sep; 6(9):782-92. PubMed ID: 17689146
[TBL] [Abstract][Full Text] [Related]
57. [Oral galantamine versus rivastigmine transdermal patch: a descriptive study at a memory clinic in The Netherlands].
Wouters CJ; Dautzenberg L; Thissen A; Dautzenberg PL
Tijdschr Gerontol Geriatr; 2010 Jun; 41(3):146-50. PubMed ID: 20593742
[TBL] [Abstract][Full Text] [Related]
58. Galantamine for Alzheimer's disease.
Loy C; Schneider L
Cochrane Database Syst Rev; 2004 Oct; (4):CD001747. PubMed ID: 15495017
[TBL] [Abstract][Full Text] [Related]
59. Efficacy of nicergoline in dementia and other age associated forms of cognitive impairment.
Fioravanti M; Flicker L
Cochrane Database Syst Rev; 2001; 2001(4):CD003159. PubMed ID: 11687175
[TBL] [Abstract][Full Text] [Related]
60. Ginkgo biloba for cognitive impairment and dementia.
Birks J; Grimley EV; Van Dongen M
Cochrane Database Syst Rev; 2002; (4):CD003120. PubMed ID: 12519586
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
